{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:12:54Z","timestamp":1772795574041,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1245\/s10434-022-12600-2","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T16:05:50Z","timestamp":1665072350000},"page":"573-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?"],"prefix":"10.1245","volume":"30","author":[{"given":"Stephanie A.","family":"Blankenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes J.","family":"Bonenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen J. B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franchette W. P. J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willeke A. M.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margreet G.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Willem B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geke A. P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen W.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier J.","family":"van Not","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djura","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozemarijn S.","family":"van Rijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A. M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel W. J. M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"10151","key":"12600_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(18)31559-9.","journal-title":"Lancet"},{"issue":"12","key":"12600_CR2","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1884\u2013901. https:\/\/doi.org\/10.1093\/annonc\/mdz411.","journal-title":"Ann Oncol"},{"issue":"4","key":"12600_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"DL Morton","year":"1992","unstructured":"Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392\u20139. https:\/\/doi.org\/10.1001\/archsurg.1992.01420040034005.","journal-title":"Arch Surg"},{"issue":"3","key":"12600_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.annonc.2020.11.015","volume":"32","author":"MA El Sharouni","year":"2021","unstructured":"El Sharouni MA, Stodell MD, Ahmed T, et al. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Ann Oncol. 2021;32(3):375\u201383. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.015.","journal-title":"Ann Oncol"},{"issue":"7","key":"12600_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1310460.","journal-title":"N Engl J Med"},{"issue":"23","key":"12600_CR6","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1613210.","journal-title":"N Engl J Med"},{"issue":"32","key":"12600_CR7","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/jco.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000\u20138. https:\/\/doi.org\/10.1200\/jco.18.02306.","journal-title":"J Clin Oncol"},{"issue":"9","key":"12600_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/s1470-2045(16)30122-x","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(16)30122-x.","journal-title":"Lancet Oncol"},{"issue":"5","key":"12600_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"issue":"7","key":"12600_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"issue":"11","key":"12600_CR11","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/s1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558\u201368. https:\/\/doi.org\/10.1016\/s1470-2045(16)30366-7.","journal-title":"Lancet Oncol"},{"issue":"16","key":"12600_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"2","key":"12600_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","volume":"5","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187\u201394. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4514.","journal-title":"JAMA Oncol"},{"issue":"9","key":"12600_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/s1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(19)30388-2.","journal-title":"Lancet Oncol"},{"issue":"5","key":"12600_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/s1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(21)00065-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"12600_CR16","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/s1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(20)30494-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"12600_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2005493.","journal-title":"N Engl J Med"},{"issue":"2","key":"12600_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256\u201363. https:\/\/doi.org\/10.1038\/s41591-020-01211-7.","journal-title":"Nat Med"},{"key":"12600_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","volume":"72","author":"A Jochems","year":"2017","unstructured":"Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer. 2017;72:156\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2016.11.021.","journal-title":"Eur J Cancer"},{"issue":"1","key":"12600_CR20","doi-asserted-by":"publisher","first-page":"Mmt38","DOI":"10.2217\/mmt-2019-0018","volume":"7","author":"EA Deckers","year":"2020","unstructured":"Deckers EA, Louwman MW, Kruijff S, Hoekstra HJ. Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. Melanoma Manag. 2020;7(1):Mmt38. https:\/\/doi.org\/10.2217\/mmt-2019-0018.","journal-title":"Melanoma Manag"},{"key":"12600_CR21","first-page":"D2420","volume":"162","author":"MCT van Zeijl","year":"2018","unstructured":"van Zeijl MCT, van den Eertwegh AJM, Wouters M, et al. Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry. Ned Tijdschr Geneeskd. 2018;162:D2420 (in Dutch).","journal-title":"Ned Tijdschr Geneeskd."},{"issue":"8","key":"12600_CR22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/sj.bjc.6605849","volume":"103","author":"A Mitra","year":"2010","unstructured":"Mitra A, Conway C, Walker C, et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer. 2010;103(8):1229\u201336. https:\/\/doi.org\/10.1038\/sj.bjc.6605849.","journal-title":"Br J Cancer"},{"issue":"4","key":"12600_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/ajd.12732","volume":"58","author":"S Zagarella","year":"2017","unstructured":"Zagarella S, Lee S, Heenan P. Sentinel lymph node biopsy status is not the most powerful predictor of prognosis in cutaneous melanoma. Australas J Dermatol. 2017;58(4):256\u20138. https:\/\/doi.org\/10.1111\/ajd.12732.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"12600_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jaad.2018.01.030","volume":"78","author":"E Stiegel","year":"2018","unstructured":"Stiegel E, Xiong D, Ya J, et al. Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. J Am Acad Dermatol. 2018;78(5):942\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.030.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"12600_CR25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jaad.2018.11.026","volume":"80","author":"M Bigby","year":"2019","unstructured":"Bigby M, Zagarella S, Sladden M, Popescu CM. Time to reconsider the role of sentinel lymph node biopsy in melanoma. J Am Acad Dermatol. 2019;80(4):1168\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.026.","journal-title":"J Am Acad Dermatol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12600-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:25:21Z","timestamp":1670347521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["12600"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12600-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephanie A. Blankenstein, Johannes J. Bonenkamp, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Olivier J. van Not, Djura Piersma, Gerard Vreugdenhil, Hans M. Westgeest, and Michel W.J.M. Wouters have declared no conflict of interest. Maureen J.B. Aarts has received advisory board\/consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, and Bayer, and research Grants from Merck-Pfizer, not related to the current work and paid to the institute. Christian U. Blank has received commercial research Grants from Novartis, BristolMyers Squibb, and NanoString; is a paid advisory board member for Bristol Myers Squibb, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, and Pierre Fabre; and holds ownership interest in Uniti Cars, Neon Therapeutics, and Forty Seven. Marye J. Boers-Sonderen has consultancy\/advisory relationships with Pierre Fabre, MSD and Novartis, all paid to the institution. Alfons J.M. van den Eertwegh has received research study Grants not related to this paper from Sanofi, Roche, Bristol-Myers Squibb, TEVA, and Idera; received travel expenses from MSD Oncology, Roche, Pfizer, and Sanofi; and received speaker honoraria from Bristol-Myers Squibb and Novartis. Margreet G. Franken has advisory relationships with Roche Nederland BV and Daiichi Sankyo, paid to the institution. Jan Willem B. de Groot has consultancy\/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, and Novartis. John B.A.G. Haanen has advisory relationships with Aimm, Achilles Therapeutics, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, BioNTech, GSK, Immunocore, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics, Pfizer, Roche\/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, and Vaximm, and has received research Grants not related to this paper from Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics, and Novartis. All Grants were paid to the institutions. Geke A.P. Hospers has consultancy\/advisory relationships with Amgen, Bristol Myers Squibb, Roche, MSD, Pfizer, Novartis, and Pierre Fabre, and has received research Grants not related to this paper from Bristol Myers Squibb and Seerave that were paid to the institution. Ellen W. Kapiteijn has consultancy\/advisory relationships with Bristol Myers Squibb, Novartis, Merck, and Pierre Fabre, and has received research Grants not related to this paper from Bristol Myers Squibb. Rozemarijn S. van Rijn has received advisory board\/consultancy honoraria from Pfizer, and an expert meeting fee from Roche. Karijn P.M. Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, and Abbvie, and has received honoraria from Novartis, MSD, and Roche, all paid to the institution. Astrid A.M. van der Veldt has consultancy relationships with Bristol Myers Squibb, MSD, Sanofi, Merck, Pfizer, Ipsen, Eisai, Roche, Pierre Fabre, and Novartis, all paid to the institute. Through Alexander C.J. van Akkooi, the Netherlands Cancer Institute (NKI) has received compensation for advisory roles from Amgen, BMS, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sirius Medical, Sanofi and 4SC, and has received Grants from Amgen and Merck-Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}